NCT04823130View on ClinicalTrials.gov

Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

PHASE4CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 22, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

August 30, 2022

Conditions
Dermatitis Atopic
Interventions
DRUG

Dupilumab (SAR231893)

Pharmaceutical form: solution for injection Route of administration: subcutaneous

Trial Locations (3)

33136

Investigational Site Number 8400001, Miami

48149

Investigational Site Number 2760001, Münster

08520

Investigational Site Number 8400002, East Windsor

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY